Trial ID or NCT#

NCT04450316

Status

recruiting iconRECRUITING

Purpose

Interstitial cystitis/Bladder Pain Syndrome (IC/PBS) is a constellation of symptoms of pelvic discomfort that includes both bladder-related pain as well as urinary frequency, urgency, and nocturia in the absence of an identifiable etiology that affects likely more than 5.4 million patients in the United States. There is a significant overlap in patients with IC/PBS and those with fibromyalgia and chronic pelvic pain syndrome. Low-dose naltrexone (LDN) has been shown to be effective for the treatment of chronic pain conditions. The primary aim of this study is to evaluate if LDN improves pain scores and lower urinary tract symptoms in patients with IC/PBS. A secondary aim is to show that it has a low adverse event profile.

Official Title

Low-dose Naltrexone for Bladder Pain Syndrome: A Randomized Placebo-controlled Prospective Pilot Trial

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Craig V. Comiter
Craig V. Comiter
Urologist, Female urologist, Urogynecologist
Professor of Urology and, by courtesy, of Obstetrics and Gynecology
Jennifer Hah
Jennifer Hah
Pain management specialist
Assistant Professor of Anesthesiology, Perioperative and Pain Medicine (Adult Pain)
Philip M. Hanno
Philip M. Hanno
Urologist
Clinical Professor, Urology

Contact us to find out if this trial is right for you.

CONTACT

Gabrielle Hettie
(650) 724-2091